FDA advisers narrowly approve Pfizer`s RSV vaccine for older adults, despite possible safety concerns
(CNN.com US)

Vaccine advisers to the US Food and Drug Administration narrowly voted Tuesday in favor of Pfizer`s RSV vaccine for adults over the age of 60, paving the way for approval of the first nation`s RSV vaccine, despite some safety concerns.